Edgewise Therapeutics Inc...

13.40
0.37 (2.84%)
At close: Apr 17, 2025, 3:59 PM
13.25
-1.14%
After-hours: Apr 17, 2025, 07:56 PM EDT
2.84%
Bid 12.05
Market Cap 1.41B
Revenue (ttm) n/a
Net Income (ttm) -133.81M
EPS (ttm) -1.45
PE Ratio (ttm) -9.24
Forward PE -6.23
Analyst Buy
Ask 14
Volume 678,389
Avg. Volume (20D) 1,781,783
Open 12.98
Previous Close 13.03
Day's Range 12.61 - 13.57
52-Week Range 10.60 - 38.12
Beta 0.33

About EWTX

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that t...

Industry Biotechnology
Sector Healthcare
IPO Date Mar 26, 2021
Employees 110
Stock Exchange NASDAQ
Ticker Symbol EWTX
Full Company Profile

Analyst Forecast

According to 8 analyst ratings, the average rating for EWTX stock is "Buy." The 12-month stock price forecast is $47.5, which is an increase of 254.35% from the latest price.

Stock Forecasts
2 weeks ago
-22.9%
Edgewise Therapeutics shares are trading lower aft... Unlock content with Pro Subscription
4 months ago
+18.36%
Edgewise Therapeutics shares are trading higher after the company reported topline results from its Phase 2 CANYON trial of Sevasemten in individuals with Becker muscular dystrophy, with the trial meeting its primary endpoint.